aod-9604 vs tirzepatide for weight loss Understanding AOD 9604: The Science of the “Fat-Burning” Peptide Fragment Chevy Chase AOD 9604 Anti-Obesity

The Phase 2 trial showed that participants at 8mg achieved an average of 22.8% body weight reduction at 48 weeks

135 roles filled across Regional Sales Directors and Therapeutic Sales Specialists

FEATURED MEDICATIONS Leave Us a Message Our mission is to elevate compounding industry standards through a unique combination of superior science and service

This relationship is constant regardless of what medication is in the syringe

Avoid injecting into: Areas of broken, irritated, or sunburned skin Sites with bruising, swelling, or active infection Scar tissue or stretch marks , which may impair absorption Moles, warts, or skin lesions The area directly around the navel (within 5 cm) Waistbands or areas subject to friction from clothing Any site showing signs of lipohypertrophy (hardened, lumpy, or thickened skin) Mild injection site reactions such as temporary redness, minor swelling, or slight itching are relatively common with subcutaneous injectables and usually resolve within a few hours to days

Use ondansetron with caution in patients with conditions that may increase the risk of QT prolongation including bradycardia, AV block, stress-related cardiomyopathy, myocardial infarction, stroke, hypocalcemia, or in patients receiving medications known to cause electrolyte imbalances